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Rad6B acts downstream of Wnt signaling to
stabilize b-catenin: Implications for a novel
Wnt/b-catenin target
Brigitte Gerard1,3, Larry Tait1,3, Pratima Nangia-Makker2,3 and Malathy PV Shekhar1,2,3*
Abstract
Background: Aberrant Wnt/b-catenin signaling is associated with breast cancer even though genetic mutations in Wnt
signaling components are rare. We have previously demonstrated that Rad6B, an ubiquitin conjugating enzyme, stabilizes
b-catenin via polyubiqutin modifications that render b-catenin insensitive to proteasomal degradation. Rad6B is a
transcriptional target of b-catenin, creating a positive feedback loop between Rad6B expression and b-catenin activation.
Methods: To isolate subpopulations expressing high or low Rad6B levels, we transfected MDA-MB-231 or WS-15
human breast cancer cells with ZsGreen fluorescent reporter vector in which the expression of ZsGreen was placed
under the control of Rad6B promoter. ZsGreenhigh and ZsGreenlow subpopulations, reflective of high and low Rad6B
promoter activity, respectively, were isolated by FACS. To determine the relevance of Wnt signaling in Rad6B-mediated
b-catenin stabilization/activation, the ZsGreenhigh cells were transfected with signaling-defective Wnt coreceptor
LRP6Δ173. Rad6B expression and promoter activity were determined by RT-PCR, Western blot and Rad6B promoter-
mediated luciferase assays. b-catenin levels and transcriptional activity were determined by Western blot and TOP/FOP
Flash reporter assays. Tumor formation and morphologies of ZsGreenlow, ZsGreenhigh, and ZsGreenhigh/LRP6Δ173 cells
compared to unsorted vector controls were evaluated in nude mice. Expression of Wnt signaling related genes was
profiled using the Wnt signaling pathway RT2 Profiler PCR arrays.
Results: ZsGreenhigh subpopulations showed high Rad6B expression and Rad6B promoter activity as compared to
ZsGreenlow cells. ZsGreenhigh (high Rad6B expressors) also showed elevated b-catenin levels and TOP/Flash activity.
Inhibiting Wnt signaling in the high Rad6B expressors decreased ZsGreen fluorescence, Rad6B gene expression,
b-catenin levels and TOP/Flash activity. Tumors derived from high Rad6B expressors were predominantly composed
of cells with epithelial mesenchymal transition (EMT) phenotype as compared to control tumors that were
composed of both cuboidal and EMT-type cells. Tumors derived from low Rad6B expressors lacked EMT
phenotype. Inhibition of LRP6 function in the high Rad6B expressors abrogated the EMT phenotype. Gene
expression profiling showed upregulation of several Wnt signaling pathway regulators in high Rad6B expressors
that were downregulated by interference of Wnt signaling with mutant LRP6 or by Rad6B silencing.
Conclusions: These data reveal a functional link between the canonical Wnt pathway and Rad6B in b-catenin
activation and breast cancer progression.
Background
The canonical Wnt signaling pathway regulates several
processes including early neoplasia. Activation of the
canonical Wnt pathway involves stabilization of b-catenin
through the binding of Wnt ligands to the cell surface
Frizzled (Fz) family receptors and low density lipoprotein
receptor (LDLR)-related protein 5 (LRP5) and LRP6. The
major output of this pathway is nuclear translocation of
b-catenin, which stimulates expression of b-catenin
responsive target genes that promote cell proliferation, dif-
ferentiation, and invasion [1-4]. In the absence of Wnt
ligands, b-catenin is phosphorylated by a multiprotein
degradation complex involving APC, Axin, GSK3b and
casein kinase 1, which marks it for ubiquitination and
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degradation by the 26S proteasome [5,6]. Although genetic
mutations of APC, Axin or b-catenin are involved in the
development of several types of cancer, they are rarely
observed in breast cancer [7]. However, compelling evi-
dence has indicated that abnormal regulation of Wnt/
b-catenin signaling can lead to mammary carcinogenesis
[8-13]. Upregulated nuclear/cytoplasmic b-catenin is
found in 40-60% of human breast cancer specimens and
correlates with poor prognosis [14,15]. This suggests that
alternate/additional mechanisms of b-catenin stabilization
may be the underlying cause(s) of aberrant b-catenin acti-
vation in breast cancer patients. Overexpression of Wnt
ligands Wnt 1, Wnt 10 b or an activated form of b-catenin
in mice results in mammary tumors [16,17]. In human
breast cancer, secreted Frizzled protein (sFRP-1), a mem-
ber of the Wnt antagonist family, is downregulated in
malignant tissues [18,19]. Expression of Wnt coreceptors
LRP6, but not LRP5, was found to be upregulated in a
subset of human breast carcinomas, and downregulation
of LRP6 was sufficient to inhibit breast carcinogenesis
[20]. We have previously demonstrated that Rad6B, a 17-
kDa ubiquitin conjugating enzyme [21], stabilizes b-cate-
nin by inducing K63-linked b-catenin polyubiquitination,
which renders b-catenin insensitive to 26S proteasomal
degradation [22]. Rad6B silencing decreases polyubiquiti-
nated b-catenin levels and activity, and suppresses the
epithelial mesenchymal transition (EMT) phenotype of
WS-15 human breast cancer cells [22]. Rad6B expression
is low in normal human breast tissues, but increases in
Rad6B expression is observed in early breast cancer with
frequent overexpression in breast carcinomas [23]. Rad6B
itself is a transcriptional target of ∃-catenin/T-Cell Factor
(24), suggesting the presence of a positive feedback loop
between Rad6B gene expression and b-catenin
stabilization.
Here we determined if Rad6B mediated b-catenin
stabilization in breast cancer cells requires intact Wnt
signaling. Using the human Rad6B promoter to direct
expression of ZsGreen reporter protein, we isolated
breast cancer subpopulations expressing high and low
levels of Rad6B, and demonstrated b-catenin activa-
tion in high Rad6B subpopulations. Further, the
Rad6B-mediated b-catenin activation requires intact
Wnt signaling since disruption of Wnt signaling in
high Rad6B expressors with a signaling defective
LRP6, decreases b-catenin levels and activity, and
Rad6B promoter-directed reporter and Rad6B gene
expression. Breast cancer subpopulations selected for
high Rad6B produce tumors with the EMT phenotype,
which is suppressed by blocking LRP6 function. These
data suggest that Rad6B functions downstream of Wnt
signaling in b-catenin stabilization and breast cancer
progression.
Methods
Cell culture
MDA-MB-231 (American Type Culture Collection),
WS-15 (Cell Core Facility of Karmanos Cancer Insti-
tute), pLKO-Rad6BshRNA and empty pLKO WS-15
human breast cancer [22] cells were maintained in Dul-
becco’s modified Eagle/F-12 medium supplemented with
5% fetal bovine serum.
Plasmids
The human Rad6B (R6B) promoter sequence (bases
-401/+9 relative to the ATG start codon +1; GenBank:
NM_003337[24]) was subcloned into the XhoI/HindIII
sites of promoterless pZsGreen1 reporter vector. The
integrity of the cloned sequence was verified by DNA
sequencing. Construction and activity of the human
Rad6B promoter subcloned into pGL3-Basic reporter
vector has been described previously [24]. LRP6Δ173
lacking the C-terminal 173 amino acids subcloned into
pcDNA3.1 and tagged at the C-terminus with myc and
polyhistidine tags was a generous gift from Dr. Anthony
Brown at Weill Medical College of Cornell University
(25). LRP6Δ173 lacks the PPP(S/T)Px(S/T) motifs that
are critical for efficient signaling [25,26].
Transfections and Fluorescence-activated cell sorting
MDA-MB-231 cells were transfected with pR6B promo-
ter-ZsGreen1 or the corresponding promoterless vector
with Metafectene (Biontex) and clones selected with
G418. Single cell suspensions of pooled clones from
R6B promoter-ZsGreen transfections were sorted in BD
FACSDiVa, and the top and bottom 10% of cells with
the highest (referred as R6B-Zshigh) and lowest (referred
as R6B-Zslow) ZsGreen fluorescence, respectively, were
collected into 50% FBS in Phosphate buffered saline and
propagated. R6B-Zshigh cells were stably transfected with
pcDNA-LRP6Δ173 or empty vector, and ZsGreen fluor-
escence analyzed by flow cytometry.
Immunohistochemistry, immunofluorescence, and
Western blotting
Immunohistochemistry and immunofluorescence analyses
were performed on paraffin-embedded xenografts or cells
as previously described [22]. For immunohistochemical
analysis, proteins were detected with appropriate biotiny-
lated secondary antibodies and HRP-conjugated streptavi-
din. Nuclei were counterstained with hematoxylin. For
immunofluorescence analysis, proteins were detected with
FITC- or Texas Red-conjugated secondary antibodies, and
counterstained with DAPI. Slides were stained in the
absence of primary antibody or with isotype-matched non-
immune IgG to assess nonspecific reactions. Images were
collected on Olympus BX60 microscope equipped with
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Sony high resolution/sensitivity CCD video camera. The
antibodies used for immunohistochemistry and/or immu-
nofluorescence were: anti-Rad6 [22,23], anti-b-catenin
(SantaCruz [22]), anti-myc tag (gift from Dr. Guri Tzivion,
University of Mississippi), anti-Vimentin (Abcam), and
anti-Snail1 (Abcam). Since our Rad6 antibody does not
distinguish the two isoforms Rad6A and Rad6B, we have
indicated the detected protein as Rad6. Mass spectrometry
analysis of proteins immunoprecipitated from human
breast cells using our anti-Rad6 antibody identified only
Rad6B peptides, indicating that Rad6B is the major iso-
form in breast cells (unpublished data). Moreover, the
expression levels of Rad6 protein correlate with the mole-
cular data (Rad6B promoter assays and Rad6B RNAi), con-
firming the identity of Rad6B detected by our antibody.
Cytosols were prepared from control, R6B-Zshigh, R6B-
Zslow, and R6B-Zshigh/LRP6Δ173 MDA-MB-231 cells, and
control, R6B-Zshigh and Rad6BshRNA WS-15 [22] cells as
previously described, and analyzed by immunoblotting for
Rad6, b-catenin, LRP6, myc-tagged mutant LRP6 or
b-actin.
Luciferase assays and gene expression analysis
To assay the transcriptional activity of ∃-catenin, cells
were transiently transfected with a mixture (40:1) of
inducible (pTOP/Flash) or mutant (pFOP/Flash) TCF-
responsive firefly luciferase (Upstate Biotechnology) and
pRLTK (Promega) vectors as previously described [22].
The R6B promoter-luciferase reporter vector [24] was
substituted for pTOP/Flash in some assays to assess
Rad6B promoter activity. All experiments were per-
formed thrice in duplicate. Firefly and Renilla activities
in lysates were assayed with a Dual Luciferase Reporter
Assay System (Promega).
Semi-quantitative RT-PCR
Total RNA was prepared from control, R6B-Zshigh and
R6B-Zshigh/LRP6Δ173 MDA-MB-231 cells with TRIzol
reagent (Invitrogen). Total RNA (1.0 μg) was reverse-tran-
scribed using Superscript III (Invitrogen), and Rad6B
cDNA was PCR amplified with +17/+33 and +114/+97
[GenBank:NM_003337] forward and reverse primers,
respectively [22]. GAPDH expression was monitored by
amplifications with forward (+186/+206) and reverse
(+320/+302) [GenBank:XM_006959] primers. The reac-
tion conditions that yielded a detectable product with the
minimum number of cycles were employed: 95°C, 1 min/
55°C, 1 min/65°C, 2 min for 21 cycles.
Real time RT-PCR analysis of Wnt signaling genes
The human Wnt signaling pathway RT2 Profiler PCR
arrays (SuperArray Bioscience) were used to profile the
expression of 84 genes related to Wnt signaling. Total
RNA was extracted from R6B-Zshigh, R6B-Zshigh/
LRP6Δ173, Rad6BshRNA MDA-MB-231 or WS-15 cells
and their controls with TRIzol. Single stranded cDNA
was synthesized from 2 μg of total RNA by using the
SuperArray reaction ready first strand cDNA synthesis
kit. The cDNAs were mixed with SuperArray RT2 Real
time SYBR Green/ROX PCR master mix and real time
PCR performed in accordance with the manufacturer’s
instructions. Thermal cycling and fluorescence detection
were performed using an ABI Prism 7700 Sequence
Detection System (Applied Biosystems), and expression
of Wnt regulated transcripts were compared between
the groups.
In vivo assays
Xenografts of MDA-MB-231 or WS-15 derived subpopu-
lations were generated by injecting 1 × 106 or 5 × 106
MDA-MB-231 or WS-15 derivatives, respectively, in
0.1 ml serum-free media or Matrigel subcutaneously near
the nipple of gland #5 of female nude mice. Xenografts
were removed at 50 days and fixed in buffered-formalin.
In vivo experiments were approved by the Institutional
Animal Care and Use Committee, and conformed to the
NIH regulatory standards.
Terminal deoxynucleotidyl transferase biotin-dUTP nick
end-labeling (TUNEL)
TUNEL staining was performed as previously described
[27]. Apoptotic cells in MDA-MB-231 xenografts were
identified on deparaffinized sections using the Deadend
fluorimetric TUNEL system (Promega). Sections were
counterstained with propidium iodide. Images were cap-
tured with an Olympus BX40 microscope and processed
with the M5+ microcomputer imaging device (Interfo-
cus Imaging, Ltd., Cambridge, U.K.).
Statistical Analysis
Data were analyzed with GraphPad software using either
Student’s t test or ANOVA. P < 0.05 was considered
significant.
Results
Tumor subpopulations with endogenous Rad6B
overexpression show elevated b-catenin levels and
activity
We have previously demonstrated a positive association
between Rad6B and b-catenin expression in breast carcino-
mas [24]. To establish the functional link between Rad6B
expression and b-catenin activity, MDA-MB-231 cells were
stably transfected with either the pZsGreen1 reporter vec-
tor in which the expression of ZsGreen1 reporter is placed
under the control of the human Rad6B promoter (Figure
1A) or the control promoterless vector. MDA-MB-231
cells were chosen because they have autocrine Wnt signal-
ing activity [28]. MDA-MB-231 subpopulations with high
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Figure 1 Breast cancer subpopulations selected for high Rad6B promoter activity display elevated b-catenin levels and activity, which
is suppressed by LRP6 inhibition. (A) Fluorescence/phase contrast images of MDA-MB-231 cells stably transfected with Rad6B promoter-
ZsGreen1 reporter vector. (B) FACS analysis of MDA-MB-231 cells transfected with promoterless (a) or Rad6B promoter-ZsGreen1 (b) vector. Panel
c, FACS profile of R6B-Zshigh cells transfected with mutant LRP6Δ173. Insets in b represent fluorescence images of sorted subpopulations with
low (Zs low) and high (Zs high) green fluorescence. (C) Rad6B mRNA expression relative to GAPDH in the indicated cells determined by semi-
quantitative RT-PCR. (D) Steady-state levels of indicated proteins in the cytosols of indicated MDA-MB-231 subpopulations. (E) Relative Rad6B
promoter activity in MDA-MB-231 cells transfected with Rad6B promoter-luciferase and pRLTK. (F) Relative pTOP/Flash or pFOP/Flash reporter
activities in MDA-MB-231 cells. The data shown in E and F are averages (± S.E.M) of three separate experiments performed in duplicate.
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(R6B-Zshigh) and low (R6B-Zslow) promoter activities were
isolated by cell sorting, and expanded for further analysis
(Figure 1Bb). As shown in Figure 1B, strong expression of
ZsGreen1 reporter is reflective of strong Rad6B promoter
activity (compare panels a and b in Figure 1B). To deter-
mine the relationship between Rad6B and Wnt signaling in
b-catenin stabilization, R6B-Zshigh cells were stably trans-
fected with LRP6Δ173, a signaling defective dominant
negative mutant of LRP6 Wnt coreceptor [25]. This
mutant LRP6 lacks the cytoplasmic tail (c-tail) containing
the stability elements that are required for Wnt1- and Dvl-
dependent signaling [25,26]. Ectopic expression of
LRP6Δ173 diminished ZsGreen1 fluorescence in R6B-
Zshigh cells (compare panels b and c in Figure 1B) suggest-
ing that disruption of Wnt signaling decreases Rad6B pro-
moter activity. RT-PCR analysis showed ~2.5 fold increase
in Rad6B mRNA levels in R6B-Zshigh cells as compared to
control MDA-MB-231 cells, and ectopic mutant
LRP6Δ173 decreased Rad6B gene expression in R6B-Zshigh
cells (P < 0.01; Figure 1C). R6B-Zshigh cells expressed
higher steady state levels of Rad6 protein as compared to
control or R6B-Zslow cells (Figure 1D), and expression of
mutant LRP6 (as confirmed by myc tag antibody) in R6B-
Zshigh cells decreased Rad6 protein levels (Figure 1D).
Simultaneous measurement of b-catenin protein levels
showed elevated levels of high molecular weight b-catenin
fraction in control and R6B-Zshigh cells as compared to
R6B-Zslow cells, and ectopic LRP6Δ173 expression in R6B-
Zshigh cells dramatically reduced the high molecular weight
b-catenin fraction (Figure 1D). The steady-state levels of
endogenous LRP6 (detected with an antibody reactive to
its C-terminus) in the MDA-MB-231 subpopulations did
not show obvious relationship with Rad6 levels. Rad6B pro-
moter activity measurements corroborated ZsGreen fluor-
escence and Rad6B gene expression data. R6B-Zshigh
MDA-MB-231 cells exhibited higher Rad6B promoter-dri-
ven luciferase expression as compared to control, and
introduction of LRP6Δ173 into R6B-Zshigh cells decreased
luciferase expression (P < 0.05; Figure 1E). The transcrip-
tional activity of endogenous b-catenin was measured by
TOP/FOP Flash reporter assays. High levels of b-catenin-
mediated TOP/Flash activity observed in R6B-Zshigh cells
were significantly downregulated by LRP6Δ173 (P < 0.01;
Figure 1F). These data suggest that interference of Wnt sig-
naling in Rad6B-overexpressing subpopulations downmo-
dulates intracellular b-catenin and Rad6B gene expression,
confirming the positive feedback relationship between
Rad6B and b-catenin levels previously reported [22,24].
We have previously demonstrated that silencing Rad6B
gene expression decreases intracellular b-catenin without
affecting the cell membrane associated b-catenin and
restores epithelial polarity [22]. To determine whether
this relationship between Rad6B and b-catenin is depen-
dent upon Wnt signaling, the R6B-Zshigh MDA-MB-231
cells (Figure 2A) were analyzed for expression/distribu-
tion of Rad6 and b-catenin by immunofluorescence stain-
ing. As expected, staining with anti-Rad6 antibody
corroborated the strong association between Rad6B
promoter-driven ZsGreen fluorescence and Rad6 protein
detected with Texas Red conjugated secondary antibody
(Figure 2Ba-a’’). R6B-Zshigh cells also displayed strong b-
catenin staining in the cytoplasm (Figure 2Bb-b’’). The
association between Rad6B and b-catenin accumulation
was also verified by immunofluorescence analysis of Rad6
and b-catenin in vector control, R6B-Zshigh and R6B-
Zslow MDA-MB-231 cells. Strong Rad6 and b-catenin
staining that colocalized at the periphery of nucleus was
observed in majority of the R6B-Zshigh cells as compared
to control cells, whereas R6B-Zslow cells displayed weak
and diffuse reactivities to Rad6 and b-catenin antibodies
(Figure 2C). To determine the effect of inhibiting Wnt
signaling on expression/distribution of Rad6 and b-cate-
nin, immunofluorescence staining was performed on
control R6B-Zshigh (Figure 3a) or R6B-Zshigh/LRP6Δ173
(Figure 3b-d) MDA-MB-231 cells. LRP6Δ173 expression
was verified by immunostaining with anti-myc tag anti-
body (Figure 3b’). Mutant LRP6 induced a dramatic drop
in ZsGreen fluorescence (compare Figure 3b, c and 3d
with Figure 3a) and concomitant Rad6 protein staining
(compare Figure 3c’-c’’’ with Figure 2Ba’). Unlike in R6B-
Zshigh cells where strong b-catenin staining was observed
in the cytoplasm (Figure 2Bb’), in R6B-Zshigh/LRP6Δ173
cells cytoplasmic b-catenin staining was diminished and
b-catenin was predominantly confined to the cell mem-
branes (Figure 3d’-d’’’). Downregulation of intracellular
b-catenin and restoration of b-catenin to the cell mem-
branes was accompanied by conversion from spindly
(mesenchymal) to cuboidal (epithelial) morphology
(compare Figure 3a with Figure 3b, c and 3d). These
alterations in b-catenin staining patterns and cell
morphologies induced by Wnt disruption resemble those
induced by Rad6B silencing [22].
Rad6B overexpressing breast cancer subpopulations
produce tumors with homogeneous epithelial
mesenchymal transition (EMT) phenotype
To analyze the functional contribution of Rad6B to
breast cancer development, vector control, R6B-Zshigh,
or R6B-Zslow MDA-MB-231 cells were implanted s.c.
into the mammary fatpads of female nude mice. Vector
control MDA-MB-231 cells produced tumors that dis-
played heterogeneity in tumor mass (Figure 4A).
Tumors arising from R6B-Zshigh cells were significantly
smaller than controls (P = 0.02), but were significantly
larger (P = 0.03) than those produced by R6B-Zslow
cells. To determine the contribution of Wnt signaling in
Rad6B mediated breast cancer progression, R6B-Zshigh/
LRP6Δ173 cells were implanted into the mammary
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Figure 2 Subpopulations selected for high endogenous Rad6B expression (ZsGreenhigh) show elevated intracellular b-catenin. (A)
ZsGreen fluorescence imaging of R6B-Zshigh MDA-MB-231 cells. a’ is ZsGreen fluorescence merged with DAPI. Magnification ×20. (B)
Immunofluorescence staining of R6B-Zshigh MDA-MB-231 cells with anti-Rad6 or anti-b-catenin, and detected with appropriate Texas Red
conjugated secondary antibody. Endogenous ZsGreen fluorescence was merged with Texas Red and DAPI. Original magnification, ×40. (C)
Immunofluorescence staining of control, R6B-Zshigh and R6B-Zslow MDA-MB-231 cells with anti-Rad6 or anti-b-catenin antibodies. Proteins were
detected with FITC (Rad6) or Texas Red (b-catenin) conjugated secondary antibodies. Original magnification, ×20.
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fatpads of female nude mice. Inhibition of LRP6 func-
tion in Rad6B-overexpressing subpopulations resulted in
a significant decrease of tumor growth (P = 0.01) as
compared to R6B-Zshigh cells (Figure 4A). Histologic
analysis revealed remarkable differences in the tumor
morphologies. Tumors derived from R6B-Zshigh cells
were mainly composed of spindle shaped cells in con-
trast to vector controls that consisted of both cuboidal
and spindle shaped cells (Figure 4B). Consistent with
their smaller size, tumors derived from R6B-Zslow cells
were sparsely populated and lacked spindle shaped cells
(Figure 4B). In agreement with the in vitro data of Fig-
ure 3, Wnt signaling-disrupted R6B-Zshigh cells pro-
duced tumors that lacked the EMT phenotype of R6B-
Zshigh cells (Figure 4B). Consistent with their EMT phe-
notype, strong expression of EMT markers Vimentin
and Snail1 was observed in R6B-Zshigh tumors as com-
pared to control tumors that expressed variable levels of
these markers (Figure 4C). Expression of Rad6, b-cate-
nin, Vimentin and Snail1 were all downregulated in
R6B-Zshigh/LRP6Δ173 tumors, and were negligible in
R6B-Zslow tumors (Figure 4C). These data suggest that
Rad6B overexpression positively contributes to tumor
growth and to EMT, and these Rad6B-mediated events
are dependent upon b-catenin activation and intact Wnt
signaling. TUNEL positive cells were detected in R6B-
Zshigh/LRP6Δ173 MDA-MB-231 derived tumors sug-
gesting that Rad6B expression and intact Wnt/b-catenin
signaling are required for tumor maintenance. Only rare
TUNEL positive cells were observed in R6B-Zslow
tumors suggesting that their reduced tumor growth is
not due to enhanced apoptosis (Figure 4D).
General relevance of Rad6B and Wnt/b-catenin link
The functional link between Rad6B and Wnt/b-catenin
signaling is not unique to MDA-MB-231 cells as indi-
cated by a similar positive relationship in cells of the
WS-15 human breast cancer line. Overexpression of
mutant LRP6Δ173 in R6B-Zshigh WS-15 cells also
induced a decline in ZsGreen-positive cells (Figure 5,
Figure 3 Wnt disruption in high Rad6B expressors decreases intracellular b-catenin, Rad6B promoter-directed ZsGreen expression, and
suppresses EMT phenotype. Immunofluorescence staining of control R6B-Zshigh or R6B-Zshigh/LRP6Δ173 MDA-MB-231 cells with anti-myc tag
(a’, b’), anti-Rad6 (c’-c’’’) or anti-b-catenin (d’-d’’’) antibodies. Proteins were detected with Texas Red conjugated secondary antibodies.
Endogenous ZsGreen fluorescence was merged with Texas Red and DAPI. Original magnification, ×20 for all panels except c’’’ and d’’’, X100.
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Figure 4 Tumors derived from high Rad6B expressors show homogeneous EMT phenotype that is suppressed by mutant LRP6. (A)
Tumor masses produced by the indicated MDA-MB-231 subpopulations. (B) Tumor morphologies of xenografts derived from the indicated MDA-
MB-231 subpopulations by H&E staining. (C) Immunohistochemical analysis of Rad6, b-catenin, Vimentin and Snail1 in vector control, R6B-Zshigh,
R6B-Zshigh/LRP6Δ173 and R6B-Zslow tumors. Original magnification ×20. (D) TUNEL staining (green) of tumors produced by the indicated MDA-
MB-231 subpopulations. Sections were counterstained with propidium iodide. Original magnification ×40.
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Figure 5 Inhibition of Wnt signaling in WS-15 breast cancer cells selected for endogenous Rad6B overexpression downregulates
Rad6B gene expression and b-catenin transcriptional activity. (A) Fluorescence imaging of vector control R6B-Zshigh (a) or R6B-Zshigh/
LRP6D173 (b) WS-15 cells. (B) Relative Rad6B promoter activities in WS-15 subpopulations. (C) Relative pTOP/Flash or pFOP/Flash activities in WS-
15 subpopulations. The data shown in C and D are averages (± S.E.M) of three separate experiments done in duplicate. (D) Steady-state levels of
indicated proteins in the cytosols of vector control, R6B-Zshigh or PLKO-Rad6BshRNA WS-15 cells. (E) Tumor morphologies of vector control (a),
R6B-Zshigh (b), and Rad6BshRNA (c) WS-15 xenografts by H&E staining. Immunohistochemical analysis of Rad6 (a’, b’ and c’) and b-catenin (a”, b”
and c”) in vector control, Rad6B-Zshigh and Rad6BshRNA WS-15 tumors. Short arrow in panel a shows hyperplastic region and long arrow shows
invasive carcinoma. Long arrow in b and b’ show blood vessels in tumors, and the short arrow in b’ shows nuclear Rad6 staining. Note the loss
of cell membrane staining of b-catenin in R6B-Zshigh tumors (compare a” and b”). Insets in c’ and c” show magnified images of Rad6 and b-
catenin staining, respectively, in hyperplastic ducts of Rad6BshRNA tumors. Original magnification ×4 (a and b); ×10 (c); ×20 (c’ and c”); ×40 (a’,
a”, b’, b”). (F) Comparison of tumor masses of vector control, R6B-Zshigh and Rad6BshRNA WS-15 derivatives.
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compare Aa and Ab). Consistent with ZsGreen reporter
expression, R6B-Zshigh WS-15 cells displayed ~2.4 fold
higher Rad6B promoter-driven luciferase expression as
compared to vector controls (P < 0.01), which was
inhibited by ectopic expression of LRP6Δ173 (Figure
5B). TOP/Flash reporter assays showed high levels of
endogenous b-catenin transcriptional activity in R6B-
Zshigh WS-15 cells as compared to controls (P < 0.01),
which was dramatically decreased by expression of
mutant LRP6 (P < 0.01; Figure 5C). Western blot analy-
sis showed the presence of higher steady state levels of
Rad6 and high molecular weight b-catenin in R6B-Zshigh
WS-15 cells as compared to vector controls, and a selec-
tive decrease in high molecular weight b-catenin frac-
tion in Rad6B silenced WS-15 cells (Figure 5D). These
data are consistent with our previous report that Rad6B
silencing selectively decreases the polyubiquitinated high
molecular weight forms of b-catenin without affecting
the nascent 90 kDa band [22].
Control WS-15 cells implanted into the mammary fat-
pads of female nude mice produce large tumors within
60 days (Figure 5F). These tumors are composed of a
small hyperplastic region (Figure 5Ea, short arrow) and a
larger malignant area (Figure 5Ea, long arrow). Similar
xenograft assays performed with R6B-Zshigh WS-15 cells
produced large tumors (Figure 5F) that were generously
populated with blood vessels (long arrows in Figure 5Eb
and 5b’), and lacked the benign hyperplastic areas
observed in control tumors (Figure 5E, compare a and b).
Immunohistochemical analysis showed strong Rad6
staining in the cytoplasm of control tumors (Figure 5Ea’)
whereas Rad6 expression was observed in the cytoplasm
and nuclei of R6B-Zshigh WS-15 tumors (short arrow in
Figure 5Eb’). Control xenografts showed strong b-catenin
staining in the cytoplasm and cell membranes (Figure
5Ea’’), whereas R6B-Zshigh tumors showed strong cyto-
plasmic b-catenin expression with loss of staining on the
cell membranes (Figure 5b’’). WS-15-Rad6BshRNA cells
produced significantly smaller tumors (P < 0.001) as
compared to vector control or R6B-Zshigh WS-15 cells
(Figure 5F). WS-15-Rad6BshRNA tumors were com-
prised of hyperplastic ducts and noticeably lacked the
malignant region observed in vector control and R6B-
Zshigh WS-15 tumors (compare Figure 5Ea and 5Eb with
5Ec). Rad6B silenced WS-15 tumors showed an overall
decrease in Rad6 and b-catenin staining as compared to
R6B-Zshigh and vector control WS-15 tumors (Figure
5Ec’ and 5c’’).
Expression of Wnt regulated genes are influenced by
Rad6B status
To analyze the link between Rad6B and Wnt signaling
pathway, we used RT2 Profiler PCR SuperArrays to pro-
file the expression of 84-Wnt related genes in vector
control, R6B-Zshigh, or R6B-Zshigh/LRP6Δ173 MDA-MB-
231 cells, or vector control or pLKO-Rad6BshRNA
WS-15 [22] breast cancer cells. Expression of several
Wnt signaling negative and positive regulators were
increased in R6B-Zshigh MDA-MB-231 cells as compared
to vector control, and disruption of LRP6 function in
R6B-Zshigh MDA-MB-231 cells resulted in dramatic
reduction in expression of these genes (Figure 6A). Wnt
positive regulators Wnt 2B, Wnt 6, Wnt 9A, Wnt 10A,
Fzd1, Fzd2, Fzd7, FBW2, Dvl-1, and cyclin D1 were upre-
gulated in R6B-Zshigh MDA-MB-231 cells, and ectopic
expression of mutant LRP6 in R6B-Zshigh cells resulted
in a dramatic drop in expression of these transcripts
(Figure 6A). Interestingly, expression of Wnt antagonists
sFRP-1, sFRP-4, KREMEN1, and ICAT were elevated in
R6B-Zshigh MDA-MB-231 cells and decreased in Wnt
disrupted R6B-Zshigh MDA-MB-231 cells (Figure 6A).
Similar analysis of Wnt signaling pathway regulators in
empty vector control and pLKO-Rad6BshRNA WS-15
cells [22] validated the data from MDA-MB-231 cells.
Expression of genes upregulated in R6B-Zshigh MDA-
MB-231 cells, viz., Wnt 2B, Wnt 6, Wnt 10A, Dvl-1,
Fzd1, Fzd7, sFRP-1, FBW2, SOX17, TCF7, and cyclin D1
were inhibited in Rad6B silenced WS-15 cells (Figure
6B). Expression of Naked, a negative regulator of Wnt
signaling [29], was induced in WS-15/Rad6BshRNA
cells and R6B-Zshigh/LRP6Δ173 MDA-MB-231 cells rela-
tive to their corresponding controls (Figures 6A and 6B).
Figure 6 Expression analysis of Wnt-regulated genes by RT2
Profiler PCR SuperArrays. (A) Relative levels in the indicated MDA-
MB-231 (A) and WS-15 (B) derivatives.
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b-catenin expression was unaffected by Rad6B overex-
pression (R6B-Zshigh MDA-MB-231 cells) or Rad6B silen-
cing (Rad6BshRNA WS-15 cells), confirming our
previous report that Rad6B induced b-catenin activation
does not involve transcriptional events [22]. LRP5 and
LRP6 expression was unaffected by Rad6B overexpression
or silencing (data not shown). Similar changes in gene
expression in MDA-MB-231 and WS-15 cells following
Wnt disruption or Rad6B silencing, respectively, suggest
that the expression of a set of genes that is regulated by
b-catenin transcriptional activity is influenced by Rad6B
status.
Discussion
In this study, we provide novel evidence for a functional
link between Wnt signaling and Rad6B in b-catenin
activation, and the potential value of using Rad6B to tar-
get the Wnt/b-catenin pathway in human breast cancer.
The data from this paper show that elevated b-catenin
levels and activity observed in Rad6B-overexpressing
breast cancer subpopulations (R6B-Zshigh) require intact
Wnt signaling since disruption of Wnt signaling in R6B-
Zshigh cells with a signaling defective LRP6 lacking 173
amino acids in the c-tail [25] dramatically inhibits
b-catenin levels and activity. The c-tail of LRP6 is a sub-
strate for Wnt induced Dvl dependent phosphorylation
[30-32]. The phosphorylated c-tail PPPSPXS motifs
recruit Axin and GSK3b [31], and inhibits GSK3b by
acting as competitive inhibitor of this kinase [33-36]
with resultant accumulation of unphosphorylated b-
catenin in the cytoplasm and translocation to the
nucleus [4,37]. Rad6B is a transcriptional target of b-
catenin [24]. Consistent with this, our present data show
that inhibition of LRP6 signaling in R6B-Zshigh breast
cancer cells induces a reduction in Rad6B promoter
activity as evidenced by decrease in Rad6B promoter-
mediated ZsGreen and luciferase reporter expressions
and Rad6B gene expression.
Rad6B is overexpressed in human breast tumors
[23,24]. To determine the functional contribution of
Rad6B in breast cancer development and progression, in
vivo assays were performed with MDA-MB-231 or WS-
15 human breast cancer cells selected for high or low
endogenous Rad6B expression. Although the tumors
produced by R6B-Zshigh MDA-MB-231 cells are smaller
than those from unselected control MDA-MB-231 cells,
it is notable that R6B-Zshigh tumors are predominantly
composed of spindle shaped cells that are typical of
EMT, and capable of metastasizing spontaneously to the
lung (1 out of 8) and lymph node (2 out of 8) of nude
mice. Epithelial to mesenchymal transition plays a criti-
cal role in regulating cell migration during neoplastic
invasion [38]. The Snail superfamily of zinc-finger tran-
scription factors is essential for induction of EMT and
invasive process [39]. Wnt signaling promotes tumor
invasion by stabilizing Snail1 in breast cancer cells [40].
R6B-Zshigh MDA-MB-231 tumors show strong Snail1
expression, which is downregulated by mutant LRP6,
whereas R6B-Zslow MDA-MB-231 tumors lack the spin-
dle shaped cells and express low or negligible Snail1.
EMT is also frequently associated with loss of E-cad-
herin [41]. However, E-cadherin expression is very low
in MDA-MB-231 cells [42]. Thus, it is likely that the
epithelial mesenchymal transitions we have observed are
a consequence of the nuclear activity of b-catenin rather
than those involving interactions with E-cadherin.
The Wnt/b-catenin is frequently activated in human
breast cancer. 40-60% of human breast cancers exhibit
nuclear/cytoplasmic b-catenin and aberrant activation of
the pathway at the receptor level is common [14,15,
24,43-45]. LRP6 expression is upregulated in basal-like
breast cancer [46]. Transgenic mice that overexpress LRP6
in mammary epithelial cells develop mammary gland
hyperplasia, but fail to develop adenocarcinoma [47] sug-
gesting the requirement for additional mechanisms for
activating the Wnt pathway. Cooperation between Rad6B
and intact Wnt signaling in breast cancer is apparent by
the development of tumors with homogeneous EMT phe-
notype from R6B-Zshigh MDA-MB-231 cells as compared
to R6B-Zshigh/LRP6Δ173 derived tumors that are growth
inhibited and lack the EMT phenotype. These findings are
consistent with the data from Liu et al [20] that inhibition
of LRP6 with the antagonist Mesd suppresses tumor
growth and Wnt1 induced signaling. Our in vivo assays
with WS-15 breast cancer cells further confirm the role of
Rad6B in breast cancer progression since R6B-Zshigh
WS-15 cells produced very angiogenic carcinomas as com-
pared to controls, whereas Rad6B silencing inhibited pro-
gression to carcinoma with resultant benign hyperplastic
tumors.
Our data from profiling of Wnt related genes show
upregulation of several Wnt signaling pathway regulators
in Rad6B overexpressing breast cancer cells, which are
downregulated either by mutant LRP6 or Rad6B silen-
cing. Wnt ligands are upregulated in subset of human
breast cancers [20,48]. Since suppression of LRP6 in
Rad6B overexpressing breast cancer cells results in
decreases in expression of Wnt ligands (Wnt 2B, Wnt 6,
Wnt 9A, Wnt 10A), b-catenin transcriptional activity and
tumor growth suggests that overexpression of Rad6B and
Wnt ligands may act in concert to influence breast can-
cer progression. Wnt5A expression was not affected by
LRP6 suppression or Rad6B gene silencing, suggesting
that Wnt 5A is not a critical regulator of the canonical
Wnt pathway in MDA-MB-231 or WS-15 cells. The Wnt
negative regulator sFRP-1 is reduced or lost in 80% of
breast carcinomas [18,49]. However, our data showed
that sFRP-1 is overexpressed in Rad6B overexpressing
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cells, and downregulated by Rad6B silencing or LRP6
suppression. This is consistent with a negative feedback
response that may act to restrict the exposure of cells to
a prolonged Wnt growth factor signal. Nevertheless,
despite overexpression of sFRPs in R6B-Zshigh cells, the
net outcome is one of increased b-catenin activity and
tumor progression.
The MDA-MB-231 cell line belongs to a subset of tri-
ple negative breast cancers that also express Vimentin
[50]. This subset is thought to represent breast cancers
that have undergone EMT and has been associated with
clinical disease that is more invasive, has a higher mito-
tic index, and also a worse clinical outcome [51,52].
Rad6B gene expression is induced by TCF/b-catenin
[24]. Rad6B in turn stabilizes b-catenin by polyubiquitin
modifications that protect b-catenin from proteasomal
degradation [22], thus setting off a vicious positive feed-
back loop between Rad6B expression and b-catenin acti-
vation (Figure 7). Our data demonstrate that selection of
Rad6B overexpressing subpopulations selectively
enriches for MDA-MB-231 subpopulations that exhibit
homogeneous EMT phenotype and possess elevated
b-catenin activity. Interference of Wnt signaling in
Rad6B overexpressing subpopulations by a signaling
deficient LRP6 decreases intracellular b-catenin, Rad6B
gene expression, and inhibits EMT. Since similar out-
comes on b-catenin activity and loss of EMT phenotype
are achieved by Rad6B gene silencing [22], further con-
firm that Rad6B is a downstream mediator of b-catenin
activation in the canonical Wnt signaling pathway
(Figure 7).
Conclusions
Taken together that similar outcomes on b-catenin
activity, EMT suppression, or breast cancer progression
are achieved by inhibiting LRP6 or Rad6B [22], illustrate
the cooperation between the canonical Wnt signaling
pathway and Rad6B in b-catenin activation. These data
Figure 7 Model of Rad6B/b-catenin regulation in breast cancer cells with autocrine Wnt activity. Activation of the canonical Wnt pathway
is regulated by Wnt ligand interactions with Wnt receptors Frizzled (FZD) and coreceptors LRP5/6 at the cell surface, and culminates in b-catenin
stabilization by preventing its recruitment into the APC/Axin/GSK3 destruction complex. Rad6B transcription is induced by b-catenin, and Rad6B
in turn stabilizes b-catenin by mediating K63 linked polyubiqitin modifications that render b-catenin insensitive to proteasomal degradation.
Rad6B silencing disrupts the positive feedback loop between Rad6B expression and b-catenin stabilization with resultant decrease in
ubiquitinated b-catenin and b-catenin transcriptional activity. The Rad6B induced b-catenin stabilization occurs downstream of Wnt activation
and requires LRP6 mediated protection of b-catenin from incorporation into the destruction complex, as inhibition of LRP6 function in Rad6B
overexpressors prevents b-catenin stabilization with resultant decreases in Rad6B expression.
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suggest that antagonizing Rad6B or LRP6 function may
be beneficial for treatment of a subset of triple negative
breast cancers or breast cancers with autocrine Wnt
activity.
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